Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
Identifieur interne : 002016 ( Main/Exploration ); précédent : 002015; suivant : 002017Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
Auteurs : Erik Stroes [Pays-Bas] ; John R. Guyton [États-Unis] ; Norman Lepor [États-Unis] ; Fernando Civeira [Espagne] ; Daniel Gaudet [Canada] ; Gerald F. Watts [Australie] ; Marie T. Baccara-Dinet [France] ; Guillaume Lecorps [France] ; Garen Manvelian [États-Unis] ; Michel Farnier [France]Source :
- Journal of the American Heart Association [ 2047-9980 ] ; 2016.
Abstract
The PCSK9 antibody alirocumab (75 mg every 2 weeks; Q2W) as monotherapy reduced low-density lipoprotein-cholesterol (LDL-C) levels by 47%. Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 mg Q4W in patients with inadequately controlled hypercholesterolemia and not on statin (majority with statin-associated muscle symptoms), receiving treatment with fenofibrate, ezetimibe, or diet alone.
DOI: 10.1161/JAHA.116.003421
PubMed: 27625344
Affiliations:
- Australie, Canada, Espagne, France, Pays-Bas, États-Unis
- Bourgogne, Bourgogne-Franche-Comté, Californie, Caroline du Nord, Hollande-Septentrionale, Languedoc-Roussillon, Occitanie (région administrative), État de New York
- Amsterdam, Dijon, Montpellier
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001945
- to stream PubMed, to step Curation: 001921
- to stream PubMed, to step Checkpoint: 001921
- to stream Ncbi, to step Merge: 003B40
- to stream Ncbi, to step Curation: 003B40
- to stream Ncbi, to step Checkpoint: 003B40
- to stream Main, to step Merge: 002015
- to stream Main, to step Curation: 002016
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.</title><author><name sortKey="Stroes, Erik" sort="Stroes, Erik" uniqKey="Stroes E" first="Erik" last="Stroes">Erik Stroes</name><affiliation wicri:level="3"><nlm:affiliation>Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands e.s.stroes@amc.uva.nl.</nlm:affiliation><country wicri:rule="url">Pays-Bas</country><wicri:regionArea>Department of Vascular Medicine, Academic Medical Center, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Guyton, John R" sort="Guyton, John R" uniqKey="Guyton J" first="John R" last="Guyton">John R. Guyton</name><affiliation wicri:level="2"><nlm:affiliation>Duke University Medical Center, Durham, NC.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Duke University Medical Center, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Lepor, Norman" sort="Lepor, Norman" uniqKey="Lepor N" first="Norman" last="Lepor">Norman Lepor</name><affiliation wicri:level="2"><nlm:affiliation>Westside Medical Associates of Los Angeles Cedars-Sinai Heart Institute, Beverly Hills, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Westside Medical Associates of Los Angeles Cedars-Sinai Heart Institute, Beverly Hills</wicri:cityArea></affiliation></author><author><name sortKey="Civeira, Fernando" sort="Civeira, Fernando" uniqKey="Civeira F" first="Fernando" last="Civeira">Fernando Civeira</name><affiliation wicri:level="1"><nlm:affiliation>Lipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Lipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza</wicri:regionArea><wicri:noRegion>Zaragoza</wicri:noRegion></affiliation></author><author><name sortKey="Gaudet, Daniel" sort="Gaudet, Daniel" uniqKey="Gaudet D" first="Daniel" last="Gaudet">Daniel Gaudet</name><affiliation wicri:level="1"><nlm:affiliation>ECOGENE-21 Clinical and Translational Research Center and Department of Medicine, Université de Montréal, Chicoutimi, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>ECOGENE-21 Clinical and Translational Research Center and Department of Medicine, Université de Montréal, Chicoutimi, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name><affiliation wicri:level="1"><nlm:affiliation>Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth</wicri:regionArea><wicri:noRegion>Perth</wicri:noRegion></affiliation></author><author><name sortKey="Baccara Dinet, Marie T" sort="Baccara Dinet, Marie T" uniqKey="Baccara Dinet M" first="Marie T" last="Baccara-Dinet">Marie T. Baccara-Dinet</name><affiliation wicri:level="3"><nlm:affiliation>Sanofi, Clinical Development, R&D, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sanofi, Clinical Development, R&D, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Lecorps, Guillaume" sort="Lecorps, Guillaume" uniqKey="Lecorps G" first="Guillaume" last="Lecorps">Guillaume Lecorps</name><affiliation wicri:level="1"><nlm:affiliation>Sanofi, Chilly-Mazarin, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sanofi, Chilly-Mazarin</wicri:regionArea><wicri:noRegion>Chilly-Mazarin</wicri:noRegion><wicri:noRegion>Chilly-Mazarin</wicri:noRegion></affiliation></author><author><name sortKey="Manvelian, Garen" sort="Manvelian, Garen" uniqKey="Manvelian G" first="Garen" last="Manvelian">Garen Manvelian</name><affiliation wicri:level="2"><nlm:affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Regeneron Pharmaceuticals Inc, Tarrytown</wicri:cityArea></affiliation></author><author><name sortKey="Farnier, Michel" sort="Farnier, Michel" uniqKey="Farnier M" first="Michel" last="Farnier">Michel Farnier</name><affiliation wicri:level="3"><nlm:affiliation>Lipid Clinic, Point Médical, Dijon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Lipid Clinic, Point Médical, Dijon</wicri:regionArea><placeName><region type="region">Bourgogne-Franche-Comté</region><region type="old region">Bourgogne</region><settlement type="city">Dijon</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27625344</idno><idno type="pmid">27625344</idno><idno type="doi">10.1161/JAHA.116.003421</idno><idno type="wicri:Area/PubMed/Corpus">001945</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001945</idno><idno type="wicri:Area/PubMed/Curation">001921</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001921</idno><idno type="wicri:Area/PubMed/Checkpoint">001921</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001921</idno><idno type="wicri:Area/Ncbi/Merge">003B40</idno><idno type="wicri:Area/Ncbi/Curation">003B40</idno><idno type="wicri:Area/Ncbi/Checkpoint">003B40</idno><idno type="wicri:Area/Main/Merge">002015</idno><idno type="wicri:Area/Main/Curation">002016</idno><idno type="wicri:Area/Main/Exploration">002016</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.</title><author><name sortKey="Stroes, Erik" sort="Stroes, Erik" uniqKey="Stroes E" first="Erik" last="Stroes">Erik Stroes</name><affiliation wicri:level="3"><nlm:affiliation>Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands e.s.stroes@amc.uva.nl.</nlm:affiliation><country wicri:rule="url">Pays-Bas</country><wicri:regionArea>Department of Vascular Medicine, Academic Medical Center, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Guyton, John R" sort="Guyton, John R" uniqKey="Guyton J" first="John R" last="Guyton">John R. Guyton</name><affiliation wicri:level="2"><nlm:affiliation>Duke University Medical Center, Durham, NC.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Duke University Medical Center, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Lepor, Norman" sort="Lepor, Norman" uniqKey="Lepor N" first="Norman" last="Lepor">Norman Lepor</name><affiliation wicri:level="2"><nlm:affiliation>Westside Medical Associates of Los Angeles Cedars-Sinai Heart Institute, Beverly Hills, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Westside Medical Associates of Los Angeles Cedars-Sinai Heart Institute, Beverly Hills</wicri:cityArea></affiliation></author><author><name sortKey="Civeira, Fernando" sort="Civeira, Fernando" uniqKey="Civeira F" first="Fernando" last="Civeira">Fernando Civeira</name><affiliation wicri:level="1"><nlm:affiliation>Lipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Lipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza</wicri:regionArea><wicri:noRegion>Zaragoza</wicri:noRegion></affiliation></author><author><name sortKey="Gaudet, Daniel" sort="Gaudet, Daniel" uniqKey="Gaudet D" first="Daniel" last="Gaudet">Daniel Gaudet</name><affiliation wicri:level="1"><nlm:affiliation>ECOGENE-21 Clinical and Translational Research Center and Department of Medicine, Université de Montréal, Chicoutimi, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>ECOGENE-21 Clinical and Translational Research Center and Department of Medicine, Université de Montréal, Chicoutimi, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name><affiliation wicri:level="1"><nlm:affiliation>Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth</wicri:regionArea><wicri:noRegion>Perth</wicri:noRegion></affiliation></author><author><name sortKey="Baccara Dinet, Marie T" sort="Baccara Dinet, Marie T" uniqKey="Baccara Dinet M" first="Marie T" last="Baccara-Dinet">Marie T. Baccara-Dinet</name><affiliation wicri:level="3"><nlm:affiliation>Sanofi, Clinical Development, R&D, Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sanofi, Clinical Development, R&D, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Lecorps, Guillaume" sort="Lecorps, Guillaume" uniqKey="Lecorps G" first="Guillaume" last="Lecorps">Guillaume Lecorps</name><affiliation wicri:level="1"><nlm:affiliation>Sanofi, Chilly-Mazarin, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sanofi, Chilly-Mazarin</wicri:regionArea><wicri:noRegion>Chilly-Mazarin</wicri:noRegion><wicri:noRegion>Chilly-Mazarin</wicri:noRegion></affiliation></author><author><name sortKey="Manvelian, Garen" sort="Manvelian, Garen" uniqKey="Manvelian G" first="Garen" last="Manvelian">Garen Manvelian</name><affiliation wicri:level="2"><nlm:affiliation>Regeneron Pharmaceuticals Inc, Tarrytown, NY.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Regeneron Pharmaceuticals Inc, Tarrytown</wicri:cityArea></affiliation></author><author><name sortKey="Farnier, Michel" sort="Farnier, Michel" uniqKey="Farnier M" first="Michel" last="Farnier">Michel Farnier</name><affiliation wicri:level="3"><nlm:affiliation>Lipid Clinic, Point Médical, Dijon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Lipid Clinic, Point Médical, Dijon</wicri:regionArea><placeName><region type="region">Bourgogne-Franche-Comté</region><region type="old region">Bourgogne</region><settlement type="city">Dijon</settlement></placeName></affiliation></author></analytic><series><title level="j">Journal of the American Heart Association</title><idno type="eISSN">2047-9980</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The PCSK9 antibody alirocumab (75 mg every 2 weeks; Q2W) as monotherapy reduced low-density lipoprotein-cholesterol (LDL-C) levels by 47%. Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 mg Q4W in patients with inadequately controlled hypercholesterolemia and not on statin (majority with statin-associated muscle symptoms), receiving treatment with fenofibrate, ezetimibe, or diet alone.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Canada</li><li>Espagne</li><li>France</li><li>Pays-Bas</li><li>États-Unis</li></country><region><li>Bourgogne</li><li>Bourgogne-Franche-Comté</li><li>Californie</li><li>Caroline du Nord</li><li>Hollande-Septentrionale</li><li>Languedoc-Roussillon</li><li>Occitanie (région administrative)</li><li>État de New York</li></region><settlement><li>Amsterdam</li><li>Dijon</li><li>Montpellier</li></settlement></list><tree><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Stroes, Erik" sort="Stroes, Erik" uniqKey="Stroes E" first="Erik" last="Stroes">Erik Stroes</name></region></country><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Guyton, John R" sort="Guyton, John R" uniqKey="Guyton J" first="John R" last="Guyton">John R. Guyton</name></region><name sortKey="Lepor, Norman" sort="Lepor, Norman" uniqKey="Lepor N" first="Norman" last="Lepor">Norman Lepor</name><name sortKey="Manvelian, Garen" sort="Manvelian, Garen" uniqKey="Manvelian G" first="Garen" last="Manvelian">Garen Manvelian</name></country><country name="Espagne"><noRegion><name sortKey="Civeira, Fernando" sort="Civeira, Fernando" uniqKey="Civeira F" first="Fernando" last="Civeira">Fernando Civeira</name></noRegion></country><country name="Canada"><noRegion><name sortKey="Gaudet, Daniel" sort="Gaudet, Daniel" uniqKey="Gaudet D" first="Daniel" last="Gaudet">Daniel Gaudet</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name></noRegion></country><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Baccara Dinet, Marie T" sort="Baccara Dinet, Marie T" uniqKey="Baccara Dinet M" first="Marie T" last="Baccara-Dinet">Marie T. Baccara-Dinet</name></region><name sortKey="Farnier, Michel" sort="Farnier, Michel" uniqKey="Farnier M" first="Michel" last="Farnier">Michel Farnier</name><name sortKey="Lecorps, Guillaume" sort="Lecorps, Guillaume" uniqKey="Lecorps G" first="Guillaume" last="Lecorps">Guillaume Lecorps</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002016 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002016 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27625344
|texte= Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27625344" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |